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registration method enabling mapping of greatly deformed 
and sliding tissues. In this study, we developed and report on 
the results of a straightforward method to translate this 
geometrical ground truth validation to uncertainties in the 
mapped dose and relevant dosimetric endpoints. 
Materials and Methods: For 9 cervical cancer patients, T2w-
MRIs acquired before EBRT and as part of the MRI-guided BT 
procedure (BT applicator inserted) were used. A recently 
developed and anatomically validated structure-wise 
registration with vector field integration (SW+VF) was used to 
map non-rigidly the EBRT and the BT scans. From the results 
of the anatomical validation, i.e. the residual distances after 
the transformation for structures and landmarks, the 
standard deviation of the residual vectors for each 
component were calculated: σx, σy, and σz. These standard 
deviations were applied in the construction of an ellipsoid 
with radius (2σx, 2σy, 2σz), which represents the volume in 
which 95% of the observations occur. Next, as we mapped the 
dose for a given position p, we collected the doses within the 
ellipsoid centered at p's mapped position. From these 
collected values, we calculated the 5 and 95 percentiles as 
measure of the uncertainty in the mapped dose per voxel. 
The uncertainty was calculated for mapping EBRT to BT and 
vice versa. To illustrate the uncertainties for clinically 
relevant scenarios, we summarized them using root mean 
squares for D2cc and D50% for the bladder, rectum and sigmoid. 
Results: The standard deviations of the residual vectors were 
σx=2.3, σy=2.7, and σz=2.9 mm. The uncertainties for 
mapping the EBRT and BT dose distribution are summarized 
in table 1. The mapped BT dose represents the dose of a 
single BT application. In general, the uncertainties in D2cc for 
mapping BT to EBRT dose distributions are higher than for 
mapping EBRT to BT dose. This can be explained by the high 
dose gradients in the BT dose distribution and the location of 
D2cc in the EBRT dose distribution. For EBRT dose mapping the 
uncertainties in D50% are larger compared with D2cc. 
 
 
 
Conclusions: The magnitudes of the dose mapping 
uncertainties caused by the registration uncertainty 
emphasize the need of estimating these values prior to any 
clinical application of dose mapping. The proposed procedure 
gives a conservative estimate of the uncertainty by assuming 
the same registration uncertainty for all voxels, and by 
collecting all doses within the uncertainty volume. Extending 
this procedure to include voxel-wise registration uncertainty 
and its shape is part of future research. 
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Purpose/Objective: The use of high dose modulated arc 
techniques for stereotactic ablative radiation therapy (SABR) 
with flattened or unflattened beams is now common 
practice. With these approaches there is an increase in 
monitor units (MU) and in irradiation time. Consequently it is 
important to ensure that patient breathing, and motion, 
remains within acceptable limits during treatment. Here a 
new method, PUMA, was developed to predict the effect of 
motion on modulated SABR lung cancer plans (interplay 
effect). 
Materials and Methods: On four-dimensional computerised 
tomographic (4DCT) images of 12 previously treated lung 
cancer patients 23 volumetric arc therapy (VMAT) plans were 
created using the Eclipse V.10 treatment planning system 
(TPS) (Varian Medical Systems, Palo Alto, USA). On six patient 
data sets, two plans with different level of modulation were 
created. Each plan was made up of four 6MV arcs of 
approximately 200o. Five additional plans of two 10MV FFF 
(flattening filter free) arcs of approximately 200º were also 
created. The plans were verified by irradiating radiochromic 
films (EBT 3, ISP Corp USA) placed within a Quasar 
Respiratory Motion Phantom (Quasar, Modus Medical Devices) 
on a Varian Silhouette and plans with FFF beams on a 
TrueBeam (Varian). Film Analysis was performed using the 
RIT 113 software (Radiological Imaging Technology, USA). 
Each plan was delivered twice on the Quasar phantom, the 
first without movement and the second with motion of 1 cm 
peak to peak at 12 breaths per minute (BPM). A relative 
comparison between the dose distributions measured and 
those calculated on the TPS was performed and the PUMA 
method used to analyse the effect of motion on the plans. 
The results were also compared to those obtained on the 
Quasar phantom. The criteria for evaluation was set to be < 
5% of points with gamma 3%,3 mm > 1% on the comparison 
between static and dynamic dose distributions recorded on 
radiochromic films and < 5% of points with > 3% difference 
dose between PUMA and the TPS. These were compared to 
the results obtained on the Quasar phantom.  
Results: Figure 1 shows the comparison between both 
methods where, except for plan 7, they agree on the pass 
criteria. In this case PUMA, which analyses all target 
volumes, fails while the radiochromic film passes. This 
suggests that PUMA, which analyses the volumetric dose 
distribution, is more sensitive to interplay effect analysis 
than the analysis performed on one plane by using Quasar. 
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Figure 1. Comparison between the performance of 
radiochromic film and PUMA for analysis of motion effects on 
low modulated SABR lung plans 
Conclusions: PUMA can predict the interplay effect on SABR 
lung cancer patients and has the potential to be used as a 
routine method to ensure an appropriate low level of 
modulation on SABR lung plans independently of the energy. 
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Preclinical evaluation of novel anticancer agents combined to 
Ionizing Radiation (IR) is a key step in the generation of a 
sound rationale for further transfer towards the early clinical 
phases. Animal models should allow the minimal assessment 
of the toxicity hazard and provide significant signs of 
increased anti tumor efficacy, both required to address their 
clinical relevance, i.e. the therapeutic ratio of a candidate 
future combination. 
This assumption is clearly challenged by the major 
discrepancy between the amount of combinations suggested 
by preclinical data in the last decade and the fact that 
platinum based combinations remain the mostly widely used 
agents in the management of lung tumors. This not only 
illustrates the difficulties in funding the continuum from 
promising preclinical data to clinical steps, but also 
underscores the relatively low relevance of our preclinical 
models. Certainly, one of the reasons for this gap is the 
inhabitility of our preclinical models to keep up with the 
changes in the mutational landscape of lung cancer. Another 
major aspect is that most models used so far include 
immunocompromised models, which fail to recapitulate the 
importance of the tumor stroma in the processes of radiation 
response. The precise correlation between the preclinical 
judgment criteria and the medical need is also key : while 
most preclinical papers focus on tumor growth delays, the 
clinical need is to increase local control and to minimize the 
onset of metastasis. Lastly, the potential deleterious impact 
on normal tissues, both acute and long term, should also be 
properly evaluated at the preclinical stage to increase the 
accuracy of this appraisal. Preclinical models should also try 
to address the current challenges of the biomarker era and 
suggest in which biological context, and which criteria may 
be used to define the optimal biological context for patient 
selection. Importantly, integration of cisplatinum based 
chemotherapy as a reference may be useful for proper 
assessment of potential clinical gains. To conclude, 
immunological and vascular parameters can be dramatically 
affected by fractionation, fractionating irradiation is thus 
important for the evaluation of candidate combinations. 
Genetically engineered mice models and orthotopic murine 
models in immunocompetent recipient mice should markedly 
contribute to an improvement of the output of these murine 
models and eventually increase the success rates of future 
clinical trials while avoiding the transfer of uneffective or 
hazardous combinations to the patient. 
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Non-small cell lung cancer (NSCLC) is a group of different 
histologic tumor types with diverse molecular aberrations.  
Lung adenocarcinomas are now classified according to driving 
molecular abnormalities (mutations, rearrangements or 
amplifications), which can be identified in more than half of 
tumors, leading to effective systemic therapies in many of 
these patients. In contrast to that, evidence for presence of 
such abnormalities in squamous cell lung carcinomas is less 
clear. Successful combination of targeted therapies, 
chemotherapy and radiation in early NSCLC should be taken 
into account in the context of molecular drivers. In 
oncogenic-driven stage III NSCLC, it is likely that effective 
systemic treatment will be combined with radical 
radiotherapy or radiochemotherapy as a sequential 
 treatment, although evidence for such approach is currently 
lacking. RTOG 1306 phase II clinical trial is currently 
randomly allocating stage III patients with tumors showing 
EGFR mutations or ALK rearrangements to either 
radiochemotherapy alone (control group) or 12 weeks of 
erlotinib (EGFR cohort) or crizotinib (ALK cohort) followed by 
definitive radiochemotherapy. In non-oncogene addicted 
NSCLC, incorporation of targeted therapies into 
radiochemotherapy schedules is very difficult to predict 
preclinically, as demonstrated by several examples, including 
negative results of the RTOG 0617 trial. This trial failed to 
show any benefit from the addition of cetuximab, a 
monoclonal antibody targeting EGFR, into radiochemotherapy 
in stage III NSCLC. Lack of good prediction of clinical data 
may result from complex interactions among targeted agents, 
chemotherapy, and radiation. One of the most promising 
strategies for the future is related to the success of immune 
checkpoint inhibitors, which show considerable promise as 
adjuvant systemic treatment after definitive 
radiochemotherapy.  
Optimization of combined radiation and chemotherapy 
programs is still a matter of ongoing discussions and 
investigations. Although concurrent radiochemotherapy is a 
standard of care in fit stage III NSCLC patients, sequential 
treatments with cytotoxic agents followed by either 
hypofractionated or hyperfractionated accelerated 
radiotherapy schedules are currently revisited.  
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Purpose/Objective: IDEAL-CRT and I-START are phase I/II 
trials investigating isotoxic dose escalation in patients with 
stage IIa-IIIb non-small cell lung cancer. In both trials the 
